Novo Nordisk Forecasts 2025 Sales Growth Of 16%-24% And Operating Profit Growth At CER Of 19-27%
Benzinga
02-05
For the 2025 outlook, sales growth is expected to be 16-24% at CER, and operating profit growth is expected to be 19-27% at CER. Sales and operating profit growth reported in Danish kroner is expected to be 3 and 5 percentage points higher than at CER, respectively.